MedTrace Logo

Targeted Radiotherapy for Recurrent Prostate Cancer

NCT05067660 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-10-05

No results posted yet for this study

Summary

The TASTEPRO pilot trial evaluates the feasibility of PSMA PET-CT (Computer tomography) targeted stereotactic radiation therapy (SABR) in management of lymph node positive prostate cancer recurrence after radical prostatectomy.

Targeted SABR is compared to current standard; template-based salvage radiation therapy. The investigators expect SABR to be of equal or better oncological outcome compared to the standard therapy with less radiation-induced side-effects. Results of the pilot trial will be used when designing larger trials on oncological efficacy and safety of PSMA PET-CT targeted SABR.

Conditions

  • Prostate Cancer Recurrence After Radical Prostatectomy

Interventions

RADIATION

Stereotactic ablative radiotherapy

Stereotactic ablative radiotherapy (SABR) is a highly focused radiation treatment that concentrates an intense dose of radiation on the recurrent tumorous lesion while limiting the dose to healthy surrounding tissues.

RADIATION

Current standard template-based salvage therapy

In the group receiving salvage radiotherapy according to current standard of care, radiation will be directed to the prostatic bed and pelvic lymph nodes according to the radiation oncologist's discretion.

Sponsors & Collaborators

  • Tampere University

    collaborator OTHER

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Teemu J Murtola, MD, PhD · Professor of Urology, Tampere University, Chief Physician, Tampere University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-12-31
Completion
2025-01-01

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05067660 on ClinicalTrials.gov